Over the last few decades, our armamentarium for the medical treatment of T2D expanded considerably, with randomized evidence on sodium–glucose co-transporter-2 (SGLT2) inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) providing convincing evidence for the prevention of CV complications. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.